Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas.
OBJECTIVE
A prospective phase II study of paclitaxel was performed in adult patients with recurrent hemispheric oligodendrogliomas.


METHODS
Twenty adult patients (14 men and six women), ages 18 to 52 years (median, 40.5), with recurrent supratentorial hemispheric oligodendrogliomas were treated. All patients had previously been treated with surgery, involved-field radiotherapy (median dose, 55 Gy; range 54 to 55 Gy) and nitrosourea-based (procarbazine, lomustine [CCNU], and vincristine [PCV-3 regimen]) chemotherapy (median number of cycles, five; range, four to six). Fourteen patients were treated adjuvantly with radiotherapy and nitrosourea-based chemotherapy; six were treated at recurrence following initial gross total resection with reoperation (subtotal resection in all), radiotherapy, and nitrosourea-based chemotherapy. Paclitaxel was administered intravenously at a dose of 175 mg/m2 every 3 to 4 weeks with neurologic and neuroradiographic evaluation every 8 weeks.


RESULTS
A median of three cycles of paclitaxel (range, two to 10) were administered. All patients were assessable. Toxicity included partial alopecia (12 patients), thrombocytopenia (six), neutropenia (three), and anemia (one). One patient developed neutropenic fever without bacteriologic documentation and four required transfusion of blood products (RBCs, n = 2; platelet, n = 2). No treatment-related deaths occurred. Ten patients (50%) demonstrated either a neuroradiographic partial response (n = 3) or stable disease (n = 7), with a median response and stable disease duration of 10 months (range, 5 to 14).


CONCLUSIONS
Paclitaxel demonstrated modest efficacy with minimal toxicity in this pretreated cohort of adult patients with recurrent hemispheric oligodendrogliomas.
Chamberlain
M C
MC
University of California, San Diego, La Jolla 92093-8421, USA. marc_chamberlain@cis.ucsd.edu
Kormanik
P A
PA
D000328:Adult; D000505:Alopecia / Q000139:chemically induced; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001932:Brain Neoplasms / Q000188:drug therapy*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008130:Lomustine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009503:Neutropenia / Q000139:chemically induced; D009837:Oligodendroglioma / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011344:Procarbazine / Q000627:therapeutic use; D016879:Salvage Therapy; D013921:Thrombocytopenia / Q000139:chemically induced; D014750:Vincristine / Q000627:therapeutic use
D000972:Antineoplastic Agents, Phytogenic; D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine; D017239:Paclitaxel